ArticleFrontiers in pediatrics2026
Initial presentation, etiology and risk factors for adverse outcomes in infection-associated plastic bronchitis in children: a retrospective study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To summarize the pathogen distribution, imaging features, radiologic outcomes, and risk factors for poor prognosis in children with infection-associated plastic bronchitis (PB). Methods: This retrospective study included 86 hospitalized children diagnosed with infection-associated PB at Henan Children's Hospital from January 2021 to December 2023. Patients were grouped based on radiologic findings and outcomes into favorable prognosis, poor prognosis, and indeterminate outcome groups. Clinical data and laboratory results were compared between the favorable and poor prognosis groups to identify potential risk factors for adverse outcomes. Results: Among 86 children with infection-associated PB, 81 (94.2%) were caused by Mycoplasma pneumoniae (MP), including 29 (35.8%) co-infections. Of the MP-associated cases, 65 (80.2%) showed a good outcome, and 10 (12.3%) had unclear outcomes, while 6 (7.4%) developed adverse outcomes. These included 1 case requiring surgery, 3 with persistent atelectasis, 1 with both atelectasis and bronchiectasis, and 1 with persistent bronchiectasis. Patients with adverse outcomes exhibited significantly higher levels of LDH (788.5 U/L vs. 408 U/L, Conclusion: Mycoplasma pneumoniae is the predominant pathogen in infection-associated PB. All patients with poor outcomes were infected with M. pneumoniae. Although most children responded well to treatment, a subset developed long-term complications such as bronchiectasis and atelectasis, even requiring lobectomy. Elevated LDH and D-dimer levels may serve as early biomarkers for predicting unfavorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.